Transactions
9
Insider / Edwards Lifesciences Corp
Dahl Andrew M.
SVP, Corporate Controller at Edwards Lifesciences Corp
- Company
- Edwards Lifesciences Corp
- Ticker
- EW
- First filing on record
- November 13, 2025
- Latest trade on record
- September 13, 2026
- SEC filings
- EDGAR ↗
Dahl Andrew M., SVP, Corporate Controller at Edwards Lifesciences Corp, has disclosed 9 transactions in EW since November 13, 2025: 0 purchases (0 open-market buys) and 5 sales, worth about $158K at the reported prices. The latest was filed September 14, 2026, 1 day after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
0.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Dahl Andrew M. made no purchases and 5 sales worth $158K, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Dahl Andrew M. has traded 1 stock on record; the largest by dollars is EW.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 14,910 | — |
| F | Shares withheld for tax | 3 | 718 | $59K |
| S | Open-market sale | 2 | 1,112 | $98K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 8 | 0 | 5 · $158K |
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| EW | Sell F | September 13, 2026 | September 14, 2026 | 1d | 253 | $84 | $21K | Form 4 ↗ | ||
| EW | Sell S | August 31, 2026 | August 31, 2026 | 0d | 544 | $91 | $50K | Form 4 ↗ | ||
| EW | Sell S | May 29, 2026 | May 29, 2026 | 0d | 568 | $86 | $49K | Form 4 ↗ | ||
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 6,745 | — | — | derivative | Form 4 ↗ | |
| EW | Sell F | May 8, 2026 | May 8, 2026 | 0d | 289 | $83 | $24K | Form 4 ↗ | ||
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 3,020 | — | — | Form 4 ↗ | ||
| EW | Other A | May 7, 2026 | May 8, 2026 | 1d | 3,985 | — | — | Form 4 ↗ | ||
| EW | Sell F | February 22, 2026 | February 23, 2026 | 1d | 176 | $80 | $14K | Form 4 ↗ | ||
| EW | Other A | November 13, 2025 | November 13, 2025 | 0d | 1,160 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 14, 2026 | Form 4 | 0001225208-26-007811 | 1 | published | EDGAR ↗ |
| August 31, 2026 | Form 4 | 0001225208-26-007408 | 1 | published | EDGAR ↗ |
| May 29, 2026 | Form 4 | 0001225208-26-005647 | 1 | published | EDGAR ↗ |
| May 8, 2026 | Form 4 | 0001225208-26-005044 | 4 | published | EDGAR ↗ |
| February 23, 2026 | Form 4 | 0001225208-26-002408 | 1 | published | EDGAR ↗ |
| November 13, 2025 | Form 4 | 0001225208-25-009137 | 1 | published | EDGAR ↗ |
Other insiders at Edwards Lifesciences Corp
- Lippis Daniel J. CVP, JAPAC 52 rows
- Zovighian Bernard J CEO 35 rows
- Ullem Scott B. Director 31 rows
- BOBO DONALD E JR CVP,Strategy/Corp Development 30 rows
- Mistras Theodora Chief Financial Officer 23 rows
- Chopra Daveen CVP, TMTT & Surgical 16 rows
- Markowitz Wayne CVP, JAPAC 14 rows
- Bruls Annette CVP, EMEACLA 6 rows
- Feinberg David T Director 5 rows
- GALLAHUE KIERAN Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: Edwards Lifesciences Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 9 | November 13, 2025 | September 14, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.